. Author manuscript; available in PMC: 2021 Feb 5.

Published in final edited form as: ACS Chem Neurosci. 2020 Jan 15;11(3):427–435. doi: 10.1021/acschemneuro.9b00639

Table 3:

Study population and clinical data

Subject	Site	Gender	Age / y	Body weight / kg	Condition	β-Amyloid PET	Tau PET	[¹⁸F]NML PET	Dose / MBq	Injected mass / μg
HC-1	PM	F	52	47	HC	NA	NA	15/04/16	339	0.16
HC-2	PM	F	63	70	HC	NA	NA	21/04/16	308	1.61
HC-3	UM	F	67	68	HC	NA	NA	03/07/18	384	1.87
HC-4	UM	M	62	90	HC	NA	NA	11/07/18	386	1.38
AD-1	PM	F	72	52	AD	+	+	19/04/16	316	1.25
AD-2	PM	F	78	61	AD	+	+	12/05/16	199	0.76
AD-3	PM	F	66	65	AD	NA	NA	13/05/16	323	1.54
AD-4	UM	M	84	99	MCI	+	+	18/10/18	399	1.05
AD-5	UM	F	66	73	MCI	+	+	02/11/18	399	2.67
AD-6	UM	F	80	48	MCI	+	+	12/11/18	400	1.58
PSP-1	UM	M	76	76	PSP	NA	+	19/9/19	403	8.27